GOLPH3 and glioblastoma: The angiopep-2 was the peptide chosen for active targeting the GOLPH3-siRNA-liposomes to glioblastoma cells because of its specific binding to LRP-1 receptors expressed in the blood–brain barrier and tumor cells.